Abstract
Case Presentation. A 69-year-old Hispanic male, with a past history of diabetes and coronary disease, was admitted for fever, diarrhea, and confusion of 4 weeks duration. Physical examination showed a disoriented patient with multiple ecchymoses, possible ascites, and bilateral scrotal swelling. Hemoglobin was 6.7, prothrombin time (PT) 21.4 seconds with international normalized ratio 2.1, partial thromboplastin time (PTT) 55.6 seconds, fibrin split 10 µg/L, and lactate dehydrogenase (LDH) 1231 IU/L. Except for a positive DNA test for Epstein–Barr virus (EBV) infection, extensive diagnostic workup for infections, malignancy, or a neurological cause was negative. Mixing studies revealed a nonspecific inhibitor of PT and PTT but Factor VIII levels were normal. The patient was empirically treated with antibiotics but developed hypotension and died on day 27 of admission. At autopsy, patient was found to have intravascular diffuse large B-cell lymphoma involving skin, testes, lung, and muscles. The malignant cells were positive for CD20, CD791, Mum-1, and Pax-5 and negative for CD3, CD5, CD10, CD30, and Bcl-6. The malignant cells were 100% positive for Ki-67. Discussion. Intravascular large cell B-cell lymphoma (IVLBCL) is rare form of diffuse large B-cell lymphoma and tends to proliferate within small blood vessels, particularly capillaries and postcapillary venules. The cause of its affinity for vascular bed remains unknown. In many reports, IVLBCL was associated with HIV, HHV8, and EBV infections. The fact that our case showed evidence of EBV infection lends support to the association of this diagnosis to viral illness. The available literature on this subject is scant, and in many cases, the diagnosis was made only at autopsy. The typical presentation of this disorder is with B symptoms, progressive neurologic deficits, and skin findings. Bone marrow, spleen, and liver are involved in a minority of patients. Nearly all patients have elevated LDH, and about 65% are anemic. About 20% have hepatic and renal dysfunction. The treatment consists of systemic chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (CHOP-R) and central nervous system prophylaxis. Retrospective data suggests that, with treatment, 51% to 82% of the patients achieve a complete remission and 27% to 56% are alive at 2-year follow-up. Conclusion. IVLBCL is a difficult diagnosis to make as the disease remains confined to the vascular lumen. It may be associated with certain viral illnesses, and this association needs to be explored further. It is important to consider this diagnosis in the appropriate settings because patients may achieve durable remissions with therapy.
Highlights
Intravascular large cell B-cell lymphoma (IVLBCL) is a malignancy confined to the lumina of small blood vessels without any extravascular tumor mass or circulating lymphoma cells in the peripheral blood or bone marrow.[1]
We report a case of IVLBCL in a patient presenting as fever of unknown origin
A high lactate dehydrogenase (LDH) level suggested a hematologic malignancy as other possibilities had been ruled out
Summary
Intravascular large cell B-cell lymphoma (IVLBCL) is a malignancy confined to the lumina of small blood vessels without any extravascular tumor mass or circulating lymphoma cells in the peripheral blood or bone marrow.[1]. We report a case of IVLBCL in a patient presenting as fever of unknown origin. The patient was empirically treated with broad-spectrum antibiotics but developed altered mental status and circulatory collapse. He was transferred to the intensive care unit after developing respiratory failure and shock. He was intubated and placed on mechanical ventilation and started on vasopressor support. A previously healthy 69-year-old Hispanic male presented with fever, diarrhea, anasarca, and confusion during the past 4 weeks. Physical examination showed a disoriented patient with multiple ecchymoses, ascites, scrotal swelling, and lower
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of investigative medicine high impact case reports
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.